SEATTLE — In this video, Esther M. Bowie, MD, discusses the results of the phase 3 PULSAR trial presented at the ASRS annual meeting.
The trial compared the efficacy of aflibercept 8 mg, recently approved as Eylea HD, administered every 12 weeks or 16 weeks vs. aflibercept 2 mg every 8 weeks for the treatment of neovascular age-related macular degeneration.
The majority of patients were able to maintain noninferior visual acuity through the 12-week and 16-week intervals, according to Bowie, a professor of ophthalmology at the Penn State Health Milton (Read more...)